keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium 90

keyword
https://www.readbyqxmd.com/read/29204055/combined-treatment-of-pancreatic-cancer-xenograft-with-90y-itga6b4-mediated-radioimmunotherapy-and-pi3k-mtor-inhibitor
#1
Winn Aung, Atsushi B Tsuji, Hitomi Sudo, Aya Sugyo, Yoshinori Ukai, Katsushi Kouda, Yoshikazu Kurosawa, Takako Furukawa, Tsuneo Saga, Tatsuya Higashi
AIM: To investigate the therapeutic effect of combined integrin α6β4-targeted radioimmunotherapy (RIT) and PI3K/mTOR inhibitor BEZ235 in a pancreatic cancer model. METHODS: Phosphorylation of Akt, mTOR, the downstream effectors eukaryotic initiation factor 4E binding protein 1 (4EBP1) and S6 ribosomal protein (S6) were evaluated in BxPC-3 human pancreatic cancer cells treated with Yttrium-90 (90Y) labeled anti-integrin α6β4 antibody (ITGA6B4) and BEZ235 by western blotting...
November 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29184683/selective-internal-radiation-therapy-using-yttrium-90-resin-microspheres-in-patients-with-unresectable-hepatocellular-carcinoma-a-retrospective-study
#2
Parvez S Mantry, Ashwini Mehta, Bahar Madani, Alejandro Mejia, Islam Shahin
Background: Selective internal radiation therapy (SIRT) with yttrium-90 resin (Y-90 resin) microspheres has been used as a locoregional therapy for patients with unresectable hepatocellular carcinoma (HCC). We examined patient and disease characteristics that might affect survival after Y-90 resin, as well as treatment tolerability. Methods: Data from patients with unresectable HCC treated with Y-90 resin at a single institution were reviewed retrospectively. Survival was assessed with Kaplan-Meier curves and log-rank tests...
October 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29181682/effectiveness-of-hepatic-artery-infusion-hai-versus-selective-internal-radiation-therapy-y90-for-pretreated-isolated-unresectable-colorectal-liver-metastases-iu-crclm
#3
Mashaal Dhir, Mazen S Zenati, Heather L Jones, David L Bartlett, M Haroon A Choudry, James F Pingpank, Matthew P Holtzman, Nathan Bahary, Melissa E Hogg, Herbert J Zeh, David A Geller, J Wallis Marsh, Allan Tsung, Amer H Zureikat
BACKGROUND: In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver metastasis (IU-CRCLM) remains unknown. This study sought to compare the overall survival (OS) after HAI versus Y90 for IU-CRCLM patients treated with modern chemotherapy and to perform a cost analysis of both regional methods. METHODS: This study retrospectively reviewed patients receiving HAI or Y90 in combination with modern chemotherapy as second-line therapy for IU-CRCLM...
November 27, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29158362/cd38-bispecific-antibody-pretargeted-radioimmunotherapy-for-multiple-myeloma-and-other-b-cell-malignancies
#4
Damian J Green, Shyril O'Steen, Yukang Lin, Melilssa L Comstock, Aimee L Kenoyer, Donald K Hamlin, D Scott Wilbur, Darrell R Fisher, Margaret Nartea, Mark D Hylarides, Ajay K Gopal, Theodore A Gooley, Johnnie J Orozco, Brian G Till, Kelly D Orcutt, K Dane Wittrup, Oliver W Press
Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable efficacy targeting tumor antigens, but immunogenicity and endogenous biotin blocking may limit clinical translation. We describe a new PRIT approach for the treatment of Multiple Myeloma (MM) and other B cell malignancies, for which we developed an anti-CD38 bispecific fusion protein that eliminates endogenous biotin interference and immunogenic elements. In murine xenograft models of MM and non-Hodgkin lymphoma (NHL), the CD38 bispecific construct demonstrated excellent blood clearance and tumor targeting...
November 20, 2017: Blood
https://www.readbyqxmd.com/read/29149442/assessment-of-the-relative-contribution-of-volume-and-concentration-changes-in-yttrium-90-labelled-resin-microspheres-on-ionization-chamber-measurements
#5
Nicholas Forwood, Kathy P Willowson, Michael Tapner, Dale L Bailey
No abstract text is available yet for this article.
November 17, 2017: Australasian Physical & Engineering Sciences in Medicine
https://www.readbyqxmd.com/read/29147442/metastatic-malignant-paraganglioma-a-case-report-and-review-of-literature
#6
Carlo Angelo Prades, Bassel Atassi, Hamid Nazeer
Metastasis is a rare presentation of non-secretory paraganglioma. Consequently, there is no standard of care for the treatment of metastatic malignant paraganglioma. The most widely used chemotherapy regimen for non-resectable cases includes cyclophosphamide, vincristine, and dacarbazine (CVD). CVD has been previously studied with variable therapeutic response. However, yttrium-90 (Y90) radioembolization has not been previously studied in the treatment of hepatic metastasis in patients diagnosed with malignant paraganglioma...
June 2017: World Journal of Oncology
https://www.readbyqxmd.com/read/29113660/functional-hepatic-imaging-as-a-biomarker-of-primary-and-secondary-tumor-response-to-loco-regional-therapies
#7
REVIEW
H L Lewis, M A Ghasabeh, P Khoshpouri, I R Kamel, T M Pawlik
Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29113030/recent-advances-in-transarterial-embolotherapies-in-the-treatment-of-hepatocellular-carcinoma
#8
Edward Wolfgang Lee, Sarah Khan
Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant and surgical resection offer the best clinical outcomes, a limited number of patients are amenable to these surgical treatment options due to the advanced disease at presentation. Transarterial embolotherapies including conventional transarterial chemoembolization (cTACE), bland transarterial embolization (TAE), drug-eluting beads transarterial chemoembolization (DEB-TACE) and selective internal radiation therapy (SIRT) with Yttrium 90 (90Y) have played an increasingly important role for these patients with unresectable HCC...
November 8, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29107680/grant-deny-or-reassess-the-role-of-yttrium-90-in-hepatocellular-carcinoma
#9
Ahmed Omar Kaseb
No abstract text is available yet for this article.
October 26, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29107679/efficacy-and-safety-of-selective-internal-radiotherapy-with-yttrium-90-resin-microspheres-compared-with-sorafenib-in-locally-advanced-and-inoperable-hepatocellular-carcinoma-sarah-an-open-label-randomised-controlled-phase-3-trial
#10
Valérie Vilgrain, Helena Pereira, Eric Assenat, Boris Guiu, Alina Diana Ilonca, Georges-Philippe Pageaux, Annie Sibert, Mohamed Bouattour, Rachida Lebtahi, Wassim Allaham, Hélène Barraud, Valérie Laurent, Elodie Mathias, Jean-Pierre Bronowicki, Jean-Pierre Tasu, Rémy Perdrisot, Christine Silvain, René Gerolami, Olivier Mundler, Jean-Francois Seitz, Vincent Vidal, Christophe Aubé, Frédéric Oberti, Olivier Couturier, Isabelle Brenot-Rossi, Jean-Luc Raoul, Anthony Sarran, Charlotte Costentin, Emmanuel Itti, Alain Luciani, René Adam, Maïté Lewin, Didier Samuel, Maxime Ronot, Aurelia Dinut, Laurent Castera, Gilles Chatellier
BACKGROUND: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ((90)Y) resin microspheres in patients with hepatocellular carcinoma. METHODS: SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver transplantation, or thermal ablation after a previously cured hepatocellular carcinoma (cured by surgery or thermoablative therapy), or hepatocellular carcinoma with two unsuccessful rounds of transarterial chemoembolisation...
October 26, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29097938/labelling-of-90-y-and-177-lu-dota-bioconjugates-for-targeted-radionuclide-therapy-a-comparison-among-manual-semiautomated-and-fully-automated-synthesis
#11
Michele Iori, Pier C Capponi, Sara Rubagotti, Luca Rosario Esposizione, Johanna Seemann, Riccardo Pitzschler, Thorsten Dreger, Debora Formisano, Elisa Grassi, Federica Fioroni, Annibale Versari, Mattia Asti
In spite of the hazard due to the radiation exposure, preparation of (90)Y- and (177)Lu-labelled radiopharmaceuticals is still mainly performed using manual procedures. In the present study the performance of a commercial automatic synthesizer based on disposable cassettes for the labelling of (177)Lu- and (90)Y-DOTA-conjugated biomolecules (namely, DOTATOC and PSMA-617) was evaluated and compared to a manual and a semiautomated approach. The dose exposure of the operators was evaluated as well. More than 300 clinical preparations of both (90)Y- and (177)Lu-labelled radiopharmaceuticals have been performed using the three different methods...
2017: Contrast Media & Molecular Imaging
https://www.readbyqxmd.com/read/29097087/laser-ablation-as-monotherapy-for-penile-squamous-cell-carcinoma-a-multi-center-cohort-analysis
#12
Dominic H Tang, Sylvia Yan, Sarah R Ottenhof, Désirée Draeger, Adam S Baumgarten, Juan Chipollini, Chris Protzel, Yao Zhu, Ding-Wei Ye, Oliver W Hakenberg, Simon Horenblas, Nicholas A Watkin, Philippe E Spiess
INTRODUCTION: Although the trend towards penile sparing therapy is increasing for penile squamous cell carcinoma, outcomes for laser ablation therapy have not been widely reported. We assessed the clinical outcomes of penile cancer patients treated with only laser ablation. MATERIALS AND METHODS: A retrospective review was performed on 161 patients across 5 multi-center tertiary referral centers from 1985 to 2015. All patients underwent penile sparing surgery with only laser ablation for squamous cell carcinoma of the penis...
October 30, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29067511/safety-and-efficacy-of-transarterial-radioembolization-combined-with-chemoembolization-for-bilobar-hepatocellular-carcinoma-a-single-center-retrospective-study
#13
Joon Ho Kwon, Gyoung Min Kim, Kichang Han, Jong Yun Won, Man Deuk Kim, Do Yun Lee, Junhyung Lee, Woosun Choi, Yong Seek Kim, Do Young Kim, Kwang-Hyub Han
BACKGROUND: Radioembolization induced liver disease (REILD) is a possible sequela of transarterial radioembolization (TARE), particularly in cases of whole-liver treatment. To mitigate this problem, the safety and efficacy of combined transarterial chemoembolization (TACE) and TARE were evaluated for patients with bilobar hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Nineteen patients (mean age 60 years; range 27-82 years) treated for HCC between June 2012 and September 2014 were included in the analysis...
October 24, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29052747/angiosomal-radiopathologic-analysis-of-transarterial-radioembolization%C3%A2-for-the-treatment-of-hepatocellular-carcinoma
#14
Altan F Ahmed, Naziya Samreen, Joseph R Grajo, Ivan Zendejas, Chris L Sistrom, Amy Collinsworth, Ashwini Esnakula, Jehan L Shah, Roniel Cabrera, Brian S Geller, Beau B Toskich
PURPOSE: To assess the radiopathologic correlation following Yttrium-90 transarterial radioembolization (TARE) of hepatocellular carcinoma (HCC) using variable radiodosimetry to identify imaging surrogates of histologic response. METHODS: Twelve patients with HCC underwent ablative (≥ 190 Gy) and/or non-ablative (< 190 Gy) TARE delivered in a segmental, lobar, or combined fashion as a surgical neoadjuvant or bridge to transplantation. Both targeted tumor and treatment angiosome were analyzed before and after TARE utilizing hepatocyte-specific contrast-enhanced MRI or contrast-enhanced CT...
October 20, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/29049048/urinary-excretion-of-yttrium-90-after-radioembolization-with-yttrium-90-labeled-resin-based-microspheres
#15
Oliver S Grosser, Juri Ruf, Annette Pethe, Dennis Kupitz, Heiko Wissel, Christoph Benckert, Maciej Pech, Jens Ricke, Holger Amthauer
In radioembolic therapy (RET) of hepatic malignancies using yttrium-90 (Y)-labeled resin microspheres, radiation protection is primarily concerned with avoiding contamination by radioactive spheres. However, as Y is bound to the microsphere surface by a potentially reversible ion-exchange process, the aim of this study was to assess the extent of the potential excreted activity in urine. After RET with Y-labeled resin-based microspheres, urinary excretion of free Y was prospectively analyzed in 51 interventions (n = 45 patients) by sampling urine over 48 h (two 24-h intervals) consecutively...
October 18, 2017: Health Physics
https://www.readbyqxmd.com/read/29033589/yttrium-90-radioembolization-of-unresectable-hepatocellular-carcinoma-a-single-center-experience
#16
Carsten Meyer, Claus Christian Pieper, Hojjat Ahmadzadehfar, Nina Alexandra Lampe, Eva Maria E Matuschek, Thomas Adrian Maschke, Simon Jonas Enkirch, Markus Essler, Ulrich Spengler, Hans Heinz Schild
PURPOSE: To determine the value of radioembolization (RE) for treatment of unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Records of patients undergoing RE for unresectable HCC were retrospectively reviewed. Biochemical and clinical toxicities, imaging response (according to modified Response Evaluation Criteria In Solid Tumors), time-to-progression (TTP) and overall survival (OS) were analyzed. Data were stratified according to clinical and procedural parameters...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29028102/the-ten-commandments-of-hepatic-radioembolization-expert-discussion-and-report-from-mediterranean-interventional-oncology-miolive-congress-2017
#17
J L Bilbao, R Iezzi, S N Goldberg, A Sami, O Akhan, F Giuliante, M Pompili, L Crocetti, K Malagari, V Valentini, A Gasbarrini, C Colosimo, R Manfredi
Microsphere and particle technology represent the next-generation agents that have formed the basis of interventional oncology, an evolving subspecialty of interventional radiology. One of these platforms, yttrium-90 microspheres, is increasingly being used as a treatment modality for primary and secondary liver tumors. Due to the widespread use of radioembolization, a comprehensive review of the methodologic and technical considerations seems to be mandatory. This article summarizes the expert discussion and report from Mediterranean Interventional Oncology Live Congress (MIOLive 2017) that was held in Rome, Italy, integrating evidence-reported literature and experience-based perceptions, to assist not only residents and fellows who are training in interventional radiologists but also practicing colleagues who are approaching to this intra-arterial treatment...
September 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28990969/dosimetry-in-radiosynoviorthesis-90y-vs-153sm
#18
Mirta Barbara Torres Berdeguez, Sylvia Thomas, Susie Medeiros, Lidia Vasconcellos de Sá, Felix Mas Milian, Ademir Xavier da Silva
Although there are several radionuclides suitable for radiosynoviorthesis (RSO), not all of them can irradiate deeper synovium. Yttrium-90 (Y) is the beta radionuclide with more penetration range; therefore, it is predominantly used to treat knees. The aim of this paper is to highlight several dosimetry concepts to compare Y and Sm, also discussing the feasibility of implementing a dose planning methodology for both in RSO. The MCNPX Monte Carlo nuclear code version 2.6 was used for calculating S-values from which the activity to be injected into the joint was obtained...
October 5, 2017: Health Physics
https://www.readbyqxmd.com/read/28989121/protective-effect-of-adhesive-systems-associated-with-neodymium-doped-yttrium-aluminum-garnet-laser-on-enamel-erosive-abrasive-wear
#19
Erica Crastechini, Alessandra B Borges, Klaus Becker, Thomas Attin, Carlos Rg Torres
AIM: This study evaluated the efficacy of self-etching adhesive systems associated or not associated with the neodymium-doped yttrium aluminum garnet (Nd:YAG) laser on the protection against enamel erosive/abrasive wear. MATERIALS AND METHODS: Bovine enamel specimens were demineralized with 0.3% citric acid (5 minutes). The samples were randomly assigned to eight groups (n = 20): SB - Single Bond Universal (3M/ESPE); SB+L - Single Bond Universal + laser (80 mJ/10 Hz); FB - Futurabond U (Voco); FB+L -Futurabond U + laser; GEN - G-aenial bond (GC); GEN+L -G-aenial bond + laser; L - laser irradiation; and C - no treatment...
October 1, 2017: Journal of Contemporary Dental Practice
https://www.readbyqxmd.com/read/28987953/a-novel-bioelectrochemical-system-for-chemical-free-permanent-treatment-of-acid-mine-drainage
#20
Guillermo Pozo, Sebastien Pongy, Jürg Keller, Pablo Ledezma, Stefano Freguia
The mining sector is currently under unprecedented pressure due to stringent environmental regulations. As a consequence, a permanent acid mine drainage (AMD) treatment is increasingly being regarded as a desirable target with direct benefits for the environment and the operational and economic viability of the resources sector. In this study we demonstrate that a novel bioelectrochemical system (BES) can deliver permanent treatment of acid mine drainage without chemical dosing. The technology consists of a two-cell bioelectrochemical setup to enable the removal of sulfate from the ongoing reduction-oxidation sulfur cycle to less than 550 mg L(-1) (85 ± 2% removal from a real AMD of an abandoned silver mine), thereby also reducing salinity at an electrical energy requirement of 10 ± 0...
December 1, 2017: Water Research
keyword
keyword
8545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"